Alzheimer disease: Hippocampal volume loss and Alzheimer disease progression

Nature Reviews Neurology

Volumn 5, Issue 7, 2009, Pages 361-362

  Van Der Flier, Wiesje M ^a   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN LEVEL; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; DISEASE COURSE; GENE FREQUENCY; GENOTYPE; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITY CONTROL; RISK ASSESSMENT; SHORT SURVEY; GENETICS; METABOLISM; NOTE; PATHOLOGY;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DISEASE PROGRESSION; HIPPOCAMPUS; HUMANS;

EID: 75049085568     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2009.94     Document Type: Short Survey

References (9)

1. Henneman, W. J. et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72, 999-1007 (2009).
2. Schuff, N. et al. MRi of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132, 1067-1077 (2009).
3. Barnes, J. et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol. Aging doi:10.1016/ j.neurobiolaging.2008.01.010.
4. Raber, J., Huang, Y., Ashford, J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641-650 (2004).
5. van de Pol, L. A. et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 69, 1491-1497 (2007).
6. van der Vlies, A. E. et al. Most rapid cognitive decline in APOEe4 negative Alzheimer's disease with early onset. Psychol. Med. doi:10.1017/S0033291709005492
7. Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234 (2006).
8. Verwey, N. A. et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46, 235-240 (2009)
9. Olsson, A. et al. Simultaneous measurement of (5-amyloid , total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336-345 (2005).